![]() ![]() Completed the merger with special purpose acquisition company (SPAC) Longevity Acquisition Corporation and concurrent private placement, raising total gross proceeds of approximately $39.8 million.Published preclinical research relating to second-generation immuno-oncology LBP MRx1299 improving the activity of CAR-T in animal models of cancer, in collaboration with Philipps-University Marburg, Germany, and Universitätsklinikum Würzburg, Germany.In addition, MRx-4DP0004 generated promising signals of clinical activity which support progression into Part B of the study. Part A met the primary endpoint showing MRx-4DP0004 was safe and well tolerated. Reported topline results from Part A of our Phase I/II randomized, double-blind, placebo-controlled clinical trial of MRx-4DP0004 as a treatment for asthma.The results show treatment with Blautix ® led to structural changes in the gut microbiota and greater increases in interconnectivity between taxa than placebo, in patients with IBS-C or IBS-D. ![]() Subsequently, the Company presented additional mechanistic clinical data for Blautix ® at Gastro 2021.In addition, analysis of the data by geographical region shows that earlier topline results were impacted by an unusually high placebo response in patients in the UK and Ireland, and enhanced positive signals were seen in the larger US population. ![]() The post-hoc analyses revealed strong and statistically significant activity on the key symptom of bowel habit, a potential FDA-approvable primary endpoint.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |